SCHEMBL25223673

SCHEMBL25223673

Cc1cnc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Br

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.62
▸ ALOX15 P16050 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ CASP1 P29466 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ GAA P10253 1/20 0.57
▸ LCK P06239 4/20 0.55
▸ KIT P10721 3/20 0.55
▸ MAPK14 Q16539 3/20 0.55
▸ BTK Q06187 2/20 0.55
▸ CSF1R P07333 2/20 0.55
▸ KDR P35968 2/20 0.55
▸ KCNQ3 O43525 2/20 0.55
▸ KCNQ2 O43526 2/20 0.55
▸ KCNE1 P15382 2/20 0.55
▸ KCNQ1 P51787 2/20 0.55
▸ KCNQ5 Q9NR82 1/20 0.55
▸ MEN1 O00255 1/20 0.54
▸ HTT P42858 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075626 0.85 PTGS1 (0.61) PTGS1ALOX15TSHRCASP1NPSR1
SCHEMBL15907219 0.83 MTOR (0.57) MEN1RAB9AKMT2AMTORABL1
SCHEMBL3246039 0.81 MEN1 (0.75) PTGS1ALOX15TSHRCASP1NPSR1
SCHEMBL29537019 0.79 PTGS1 (0.54) PTGS1ALOX15TSHRCASP1NPSR1
SCHEMBL25421306 0.79 PTGS1 (0.54) PTGS1ALOX15TSHRCASP1NPSR1
SCHEMBL2497760 0.79 MEN1 (0.68) PTGS1GAALCKKITMAPK14
SCHEMBL16036513 0.79 KCNQ3 (0.65) PTGS1LCKKITMAPK14BTK
SCHEMBL29071495 0.77 GAA (0.65) PTGS1GAAKITCSF1RMEN1
SCHEMBL29921350 0.77 GAA (0.65) PTGS1GAAKITCSF1RMEN1
SCHEMBL30354791 0.77 PTGS1 (1.00) PTGS1ALOX15TSHRCASP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
CN-116761801-A Heterocyclic compounds having protein kinase inhibitory activity, pharmaceutical compositions containing the same, and methods of preparing and using the same 四川科伦博泰生物医药股份有限公司 2023-09-15 — — CN disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 — — CN disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 — — EP disclosed
WO-2022188792-A1 HETEROCYCLIC COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-09-15 — — WO disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 PTGS1 2006/4885ALOX15 3731/4885TSHR 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback